NSE: PPLPHARMA | BSE: 543635

Expensive Performer

Download real time

163.05 -2.99 (-1.80%)

32.33% Fall from 52W High

1.5M NSE+BSE Volume

NSE 19 Feb, 2026 3:31 PM (IST)

21,673.4

Market Cap

High in industry

Beta 1Year

High Volatility

US FDA Observation

Piramal Pharma gets Form 483 with four observations from the US FDA for its Telangana facility See details

Piramal Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PPLPHARMA, BSE:543635 Piramal Pharma Ltd.

Search Inside the pdf :

Piramal Pharma Ltd.

30 Jan 2026

163.05

-1.80%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with...

Number of FII/FPI investors decreased from 250 to 244 in Dec 2025 qtr

Piramal Pharma Ltd.

29 Jan 2026

163.05

-1.80%

3Q below estimates; trough phase extends

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma posted a miss on revenue/EBITDA in 3QFY26, affected by low traction in CDMO business. Complex hospital generics (CHG) business was largely stable YoY, with regulatory delays keeping growth in check.

Piramal Pharma Ltd. has an average target of 228.33 from 3 brokers.

Piramal Pharma Ltd.

06 Nov 2025

163.05

-1.80%

2Q – A miss; higher opex drags earnings

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line revenue for 2QFY62. However, it delivered a miss on EBITDA/PAT for the quarter. Higher operational costs impacted the quarter’s performance.

Piramal Pharma Ltd. is trading below its 50 day SMA of 166.2

Piramal Pharma Ltd.

29 Jul 2025

163.05

-1.80%

Temporary slowdown before a sprint

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma’s (Piramal) Q1FY26 result was below our expectations. Performance was impacted due to lack of revenue from a large innovative CDMO (-5.7% YoY) molecule and delay in shipment timing in CHG business (grew 1%).

Piramal Pharma Ltd. is trading below its 50 day SMA of 166.2

Piramal Pharma Ltd.

29 Jul 2025

163.05

-1.80%

Near-term weak due to the muted CHG business

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) exhibited lower-than-expected financial performance in 1QFY26. Lower CDMO and complex hospital generics (CHG) sales led to a considerable operating deleverage.

Piramal Pharma Ltd. is trading below its 50 day SMA of 166.2

Piramal Pharma Ltd.

15 May 2025

163.05

-1.80%

Operationally, in-line 4Q; FY25 ends on a strong note

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line sales/EBITDA in 4QFY25. However, its earnings were below our estimate due to impairment of certain intangible assets during the quarter.

Piramal Pharma Ltd. is trading below its 50 day SMA of 166.2

Piramal Pharma Ltd.

30 Jan 2025

163.05

-1.80%

Piramal Pharma | Q3FY25 Result Update

Buy: Piramal Pharma Ltd.

Target

Edelweiss

CDMO business to drive growth

Piramal Pharma Ltd. is trading below its 50 day SMA of 166.2

Piramal Pharma Ltd.

24 Oct 2024

163.05

-1.80%

Operating performance above est.; FY25 guidance intact

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered better-than-expected operational performance in 2QFY25 fueled by superior traction in the CDMO segment (59% of sales). Following earnings deterioration in FY23/FY24, PIRPHARM is exhibiting healthy recovery in 1HFY25.